News
Arvinas to present preclinical data for PROTAC BCL6 degrader & ARV-393 at 2025 AACR annual meeting in Chicago: New Haven, Connecticut Wednesday, April 23, 2025, 18:00 Hrs [IST] Ar ...
designed to degrade the B-cell lymphoma 6 protein (BCL6), may effectively combine with existing lymphoma treatments to induce tumor regressions in models of diffuse large B-cell lymphoma. ARV-393 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback